Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > No questions on cancer

<< Previous

Bullboard Posts

Next >>

Post by SPCEO1on Apr 14, 2021 9:42am

176 Views

Post# 32991838

No questions on cancer

Perhaps the most remarkable thing is that the AACR data created zero excitement in the analyst community. How is that possible? You have an exciting cancer drug that just got fast tracked in the pre-clinical stage and has pretty fascinating data and no analyst wants to ask a question about that??? Hard to fathom.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"